JP2024504632A - 非アルコール性脂肪肝疾患および関連する疾患または障害を処置または改善するための化合物、組成物および方法 - Google Patents

非アルコール性脂肪肝疾患および関連する疾患または障害を処置または改善するための化合物、組成物および方法 Download PDF

Info

Publication number
JP2024504632A
JP2024504632A JP2023542860A JP2023542860A JP2024504632A JP 2024504632 A JP2024504632 A JP 2024504632A JP 2023542860 A JP2023542860 A JP 2023542860A JP 2023542860 A JP2023542860 A JP 2023542860A JP 2024504632 A JP2024504632 A JP 2024504632A
Authority
JP
Japan
Prior art keywords
sigma
subject
compound
nash
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504632A5 (https=
Inventor
フェリクス ジンヒョン キム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of JP2024504632A publication Critical patent/JP2024504632A/ja
Publication of JP2024504632A5 publication Critical patent/JP2024504632A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
JP2023542860A 2021-01-15 2022-01-14 非アルコール性脂肪肝疾患および関連する疾患または障害を処置または改善するための化合物、組成物および方法 Pending JP2024504632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163137915P 2021-01-15 2021-01-15
US63/137,915 2021-01-15
PCT/US2022/012516 WO2022155471A1 (en) 2021-01-15 2022-01-14 Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders

Publications (2)

Publication Number Publication Date
JP2024504632A true JP2024504632A (ja) 2024-02-01
JP2024504632A5 JP2024504632A5 (https=) 2025-01-17

Family

ID=82448695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542860A Pending JP2024504632A (ja) 2021-01-15 2022-01-14 非アルコール性脂肪肝疾患および関連する疾患または障害を処置または改善するための化合物、組成物および方法

Country Status (6)

Country Link
US (1) US20240307325A1 (https=)
EP (1) EP4277898A4 (https=)
JP (1) JP2024504632A (https=)
KR (1) KR20230148156A (https=)
CA (1) CA3204756A1 (https=)
WO (1) WO2022155471A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942821A (zh) * 2023-06-02 2023-10-27 深圳市第二人民医院(深圳市转化医学研究院) Sigmar1基因抑制剂在制备治疗或预防脂肪肝病的药物中的应用
WO2025194019A1 (en) * 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2026057679A1 (en) * 2024-09-11 2026-03-19 Institut National de la Santé et de la Recherche Médicale Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112122A1 (en) * 2016-12-16 2018-06-21 Drexel University Methods of identifying and treating tumors with sigma1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142861A1 (en) * 2011-12-05 2013-06-06 National Yang Ming University Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis
WO2014015157A2 (en) * 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
EP3745862B1 (en) * 2018-01-31 2024-06-26 Mayo Foundation for Medical Education and Research D1 dopamine receptor agonists for treating fibrotic pathologies
WO2020112846A1 (en) * 2018-11-27 2020-06-04 Northwestern University Small molecule modulators of sigma-1 and sigma-2 receptors and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112122A1 (en) * 2016-12-16 2018-06-21 Drexel University Methods of identifying and treating tumors with sigma1 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCERS, vol. vol. 12(8), JPN6026009961, 7 August 2020 (2020-08-07), pages 2213 - 1, ISSN: 0005815608 *
EXPERT OPIN INVESTIG DRUGS, vol. vol. 29(2), JPN6026009960, 27 January 2020 (2020-01-27), pages 107 - 110, ISSN: 0005815609 *

Also Published As

Publication number Publication date
CA3204756A1 (en) 2022-07-21
EP4277898A4 (en) 2024-12-11
EP4277898A1 (en) 2023-11-22
WO2022155471A1 (en) 2022-07-21
KR20230148156A (ko) 2023-10-24
US20240307325A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
JP7472080B2 (ja) メラノーマの処置および診断
JP7273713B2 (ja) ヘテロ二官能性化合物を用いた調整可能な内因性タンパク質分解
JP2024504632A (ja) 非アルコール性脂肪肝疾患および関連する疾患または障害を処置または改善するための化合物、組成物および方法
JP2022019654A (ja) がん処置のためのｋａｔ６阻害剤方法および組合せ
JP2019525938A (ja) ミエリン形成を促進する化合物および方法
US12077527B2 (en) Compositions and methods for inhibiting ACSS2
JP7843542B2 (ja) 四環性化合物とそれの使用
CN118369427A (zh) 肝外递送irna组合物及其使用方法
CN119343142A (zh) 治疗具有与血细胞分化相关的临床显著体征和症状的受试者的方法
US20130012709A1 (en) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
JP2016522675A (ja) 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター
WO2022018667A1 (en) Combination therapies using cdk2 and cdc25a inhibitors
AU2019414608A1 (en) Oligomeric nucleic acid molecule and application thereof
Huang et al. Design, synthesis, and biological evaluation of an orally bioavailable, potent, and selective ROCK2 inhibitor for psoriasis treatment
JP2016510327A (ja) ｐ５３再活性化のためのオリゴオキソピペラジン
TWI414292B (zh) 調控富含鳥糞嘌呤及／或鳥糞嘌呤與胞嘧啶的核酸之表現的方法及醫藥組合物
WO2019222134A1 (en) Coup-tfii receptor inhibitors and methods using same
JP2023535224A (ja) 新規使用
US20250115593A1 (en) Rocaglate derivatives and uses thereof
JP2015082971A (ja) Ａｃｓｌ１に対するアンチセンスオリゴヌクレオチド
WO2024076967A1 (en) Compositions and methods for treating or preventing nonalcoholic steatohepatitis (nash), anorexia, depression, endometriosis, and other diseases or disorders
KR20240143116A (ko) Pak4 억제제를 포함하는 비알콜성지방간 및 간섬유화 치료용 약학적 조성물
HK40095822A (zh) 治疗和诊断黑素瘤
WO2017159739A1 (ja) 抗がん剤
KR20220133171A (ko) Rad52의 퀴놀린 저해제 및 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260312